-ATG-101, a novel PD-L1/4-1BB bispecific antibody, shows potent in vivo anti-tumor efficacy in checkpoint inhibitor resistant/relapsed models while mitigating liver ...
SAN FRANCISCO and SUZHOU, China, Nov. 15, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company ...
Showcase Features the Purion and GSD Ovation Series of Ion Implanters Designed to Meet the Emerging Needs of Power Device, ...
BAODING, China and MELBOURNE, Australia, Nov. 15, 2021 /PRNewswire/ -- In Melbourne on 12th November, Australasia's independent vehicle safety authority, ...
NANJING, China, Nov. 15, 2021 /PRNewswire/ -- On November 15, 2021, Nanjing Vazyme Biotech Co., Ltd. (Vazyme) went public on the ...
Expanded Facility Provides Comprehensive Capabilities to Support Global Pharmaceutical Drug Development Programs SINGAPORE, Nov. 15, 2021 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global ...
SHANGHAI, Nov. 15, 2021 /PRNewswire/ -- Qiming Venture Partners' portfolio company Aohua Endoscopy (SHSE: 688212), a leading medical endoscope manufacturer, ...
Collaboration Will Bring Together AWS and IBM Open Data for Industries for a Comprehensive OSDU™ Data Solution ABU DHABI, United ...
-- Gannex is expected to complete Phase II trial in 100 patients in the second half of 2022 and initiate ...
-ATG-101, a novel PD-L1/4-1BB bispecific antibody, shows potent in vivo anti-tumor efficacy in checkpoint inhibitor resistant/relapsed models while mitigating liver ...
